Compare Stocks: TRDA, CVAC, AVTX, and SLDB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$19.23 +1.2%	$19.12	$9.54 ▼ $24.27	$1.02B	0.78	744,811 shs	633,218 shs
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
SLDB Solid Biosciences	$10.25 -1.6%	$9.34	$3.79 ▼ $11.45	$1.12B	2.44	866,481 shs	495,297 shs
TRDA Entrada Therapeutics	$7.13 -0.6%	$7.06	$5.02 ▼ $16.45	$279.18M	-0.25	261,480 shs	341,729 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	+1.21%	-1.84%	+2.07%	+46.79%	+82.10%
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.06%
SLDB Solid Biosciences	-1.63%	+4.91%	+17.41%	+52.99%	+78.26%
TRDA Entrada Therapeutics	-0.56%	+1.86%	+0.99%	+11.93%	+34.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$19.23 +1.2%	$19.12	$9.54 ▼ $24.27	$1.02B	0.78	744,811 shs	633,218 shs
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
SLDB Solid Biosciences	$10.25 -1.6%	$9.34	$3.79 ▼ $11.45	$1.12B	2.44	866,481 shs	495,297 shs
TRDA Entrada Therapeutics	$7.13 -0.6%	$7.06	$5.02 ▼ $16.45	$279.18M	-0.25	261,480 shs	341,729 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	+1.21%	-1.84%	+2.07%	+46.79%	+82.10%
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.06%
SLDB Solid Biosciences	-1.63%	+4.91%	+17.41%	+52.99%	+78.26%
TRDA Entrada Therapeutics	-0.56%	+1.86%	+0.99%	+11.93%	+34.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	2.85	Moderate Buy	$45.10	134.53% Upside
CVAC CureVac	1.00	Sell	N/A	N/A
SLDB Solid Biosciences	2.83	Moderate Buy	$18.18	77.38% Upside
TRDA Entrada Therapeutics	2.50	Moderate Buy	$17.75	148.95% Upside

Current Analyst Ratings Breakdown

Latest TRDA, CVAC, AVTX, and SLDB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/31/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$16.00 ➝ $26.00
8/21/2026	SLDB Solid Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$16.00 ➝ $20.00
8/13/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/12/2026	TRDA Entrada Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
8/11/2026	AVTX Avalo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	AVTX Avalo Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$50.00 ➝ $48.00
8/7/2026	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$35.00 ➝ $30.00
7/24/2026	AVTX Avalo Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/17/2026	SLDB Solid Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	AVTX Avalo Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$38.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$60K	17,188.42	N/A	N/A	$8.37 per share	2.30
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	$3.49 per share	N/A
TRDA Entrada Therapeutics	$25.42M	10.92	N/A	N/A	$5.99 per share	1.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$78.26M	-$4.37	N/A	N/A	N/A	N/A	-58.03%	-48.22%	11/5/2026 (Estimated)
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
SLDB Solid Biosciences	-$174.32M	-$1.91	N/A	N/A	N/A	N/A	-71.35%	-60.58%	11/2/2026 (Estimated)
TRDA Entrada Therapeutics	-$143.75M	-$3.96	N/A	N/A	N/A	-3,537.73%	-57.61%	-46.54%	11/5/2026 (Estimated)

Latest TRDA, CVAC, AVTX, and SLDB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AVTX Avalo Therapeutics	-$0.5827	-$0.83	-$0.2473	-$0.83	N/A	N/A
8/6/2026	Q2 2026	SLDB Solid Biosciences	-$0.4624	-$0.38	+$0.0824	-$0.38	N/A	N/A
8/5/2026	Q2 2026	TRDA Entrada Therapeutics	-$0.9738	-$1.01	-$0.0363	-$1.01	$2.32 million	$0.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	19.31	19.31
CVAC CureVac	0.03	3.70	3.69
SLDB Solid Biosciences	N/A	13.82	13.82
TRDA Entrada Therapeutics	N/A	10.89	10.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
CVAC CureVac	17.26%
SLDB Solid Biosciences	81.46%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	4.46%
CVAC CureVac	2.15%
SLDB Solid Biosciences	2.66%
TRDA Entrada Therapeutics	9.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	40	53.63 million	51.24 million	Not Optionable
CVAC CureVac	880	224.34 million	219.52 million	No Data
SLDB Solid Biosciences	100	107.23 million	104.37 million	Optionable
TRDA Entrada Therapeutics	110	38.94 million	35.24 million	Optionable

TRDA, CVAC, AVTX, and SLDB Headlines

Recent News About These Companies

Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Upgraded by Wall Street Zen

September 5 at 1:31 AM | americanbankingnews.com

Entrada Therapeutics (NASDAQ:TRDA) Upgraded at Wall Street Zen

September 5 at 1:29 AM | marketbeat.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $180,691.89 in Stock

September 4 at 6:52 AM | insidertrades.com

BlackRock Inc. Invests $19.01 Million in Entrada Therapeutics, Inc. $TRDA

September 4 at 3:20 AM | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $180,691.89 in Stock

September 3 at 9:12 PM | marketbeat.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $205,361.28 in Stock

September 3 at 9:12 PM | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 32,263 Shares of Stock

September 3 at 9:12 PM | marketbeat.com

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2 at 4:30 PM | globenewswire.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $26,168.33 in Stock

September 1, 2026 | insidertrades.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $26,168.33 in Stock

August 31, 2026 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 38,922 Shares

August 31, 2026 | marketbeat.com

Bioventures 2018 L.P. Mpm Sells 44,259 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

August 31, 2026 | marketbeat.com

300,575 Shares in Entrada Therapeutics, Inc. $TRDA Bought by Nantahala Capital Management LLC

August 29, 2026 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Rating of "Moderate Buy" by Brokerages

August 29, 2026 | marketbeat.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $102,857.14 in Stock

August 27, 2026 | insidertrades.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells 14,569 Shares of Stock

August 26, 2026 | marketbeat.com

Bioventures 2014 L.P. Mpm Sells 21,623 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

August 26, 2026 | marketbeat.com

Bioventures 2014 L.P. Mpm Sells 26,522 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

August 26, 2026 | marketbeat.com

5AM Venture Management LLC Acquires Shares of 4,056,379 Entrada Therapeutics, Inc. $TRDA

August 26, 2026 | marketbeat.com

HC Wainwright Analysts Lower Earnings Estimates for TRDA

August 12, 2026 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 10,494 Shares of Stock

August 11, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA, CVAC, AVTX, and SLDB Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$19.23 +0.23 (+1.21%)

As of 09/4/2026 04:00 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 09/3/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Solid Biosciences NASDAQ:SLDB

$10.25 -0.17 (-1.63%)

As of 09/4/2026 04:00 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Entrada Therapeutics NASDAQ:TRDA

$7.13 -0.04 (-0.56%)

As of 09/4/2026 04:00 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRDA, CVAC, AVTX, and SLDB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRDA, CVAC, AVTX, and SLDB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRDA, CVAC, AVTX, and SLDB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA, CVAC, AVTX, and SLDB Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

CureVac NASDAQ:CVAC

Solid Biosciences NASDAQ:SLDB

Entrada Therapeutics NASDAQ:TRDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRDA, CVAC, AVTX, and SLDB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRDA, CVAC, AVTX, and SLDB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRDA, CVAC, AVTX, and SLDB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA, CVAC, AVTX, and SLDB Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

CureVac NASDAQ:CVAC

Solid Biosciences NASDAQ:SLDB

Entrada Therapeutics NASDAQ:TRDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools